Review anchor
Phosphatidylinositol 3-kinase regulatory subunit beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Phosphatidylinositol 3-kinase regulatory subunit beta
CHEMBL4437
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphatidylinositol 3-kinase regulatory subunit beta as ChEMBL target CHEMBL4437, mapped to UniProt O00459. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4437
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O00459
Phosphatidylinositol 3-kinase regulatory subunit beta
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Phosphatidylinositol 3-kinase regulatory subunit beta matters
Phosphatidylinositol 3-kinase regulatory subunit beta is reviewed as Phosphatidylinositol 3-kinase regulatory subunit beta (UniProt O00459); the current evidence base includes 1 approved drug, 1616 compounds, and 20 assays, with lead potency reaching pChEMBL 9.0.
Protein context
Phosphatidylinositol 3-kinase regulatory subunit beta
Phosphatidylinositol 3-kinase regulatory subunit beta Sequence length is 728 aa.
Review this target as Phosphatidylinositol 3-kinase regulatory subunit beta, mapped to UniProt O00459. Sequence length is 728 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O00459
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 1616 compounds, and 20 assays for this target. The dominant activity type is IC50. CHEMBL5916761 is the current potency anchor at pChEMBL 9.0.
Use CHEMBL5916761 as the tractability anchor when discussing potency (pChEMBL 9.0).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 9.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Phosphatidylinositol 3-kinase regulatory subunit beta matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O00459, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1616
Total Compounds
20
Total Assays
1
Approved Drugs
IC50: 1770.0, KI: 9.0, KD: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5916761
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL5924262
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL6002533
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL4647791
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL5744071
|
8.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
INAVOLISIB
CHEMBL4650215
|
2024 |
Source Header